YOU-HOOVER-FONG SYNDROME
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Novel compound heterozygous mutations in TELO2 in a patient with severe expression of You-Hoover-Fong syndrome.
|
28944240 |
2017 |
YOU-HOOVER-FONG SYNDROME
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
YOU-HOOVER-FONG SYNDROME
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
YOU-HOOVER-FONG SYNDROME
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Novel compound heterozygous mutations in TELO2 in a patient with severe expression of You-Hoover-Fong syndrome.
|
28944240 |
2017 |
YOU-HOOVER-FONG SYNDROME
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
YOU-HOOVER-FONG SYNDROME
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
A Syndromic Intellectual Disability Disorder Caused by Variants in TELO2, a Gene Encoding a Component of the TTT Complex.
|
27132593 |
2016 |
YOU-HOOVER-FONG SYNDROME
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
A Syndromic Intellectual Disability Disorder Caused by Variants in TELO2, a Gene Encoding a Component of the TTT Complex.
|
27132593 |
2016 |
Congenital pectus excavatum
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Microcephaly
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Congenital kyphoscoliosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Global developmental delay
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Kyphoscoliosis deformity of spine
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Acquired Kyphoscoliosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Profound global developmental delay
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
TEL2, an ETS factor expressed in human leukemia, regulates monocytic differentiation of U937 Cells and blocks the inhibitory effect of TEL1 on ras-induced cellular transformation.
|
15342392 |
2004 |
leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
TEL2 is expressed in the hematopoietic system, and its expression is up-regulated in bone marrow samples of some patients with leukemia, suggesting a role in oncogenesis.
|
16234363 |
2006 |
Leukemogenesis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Recently we also showed that TEL2 cooperates with Myc in B lymphomagenesis in mice.
|
16234363 |
2006 |
Leukemogenesis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The novel ETS factor TEL2 cooperates with Myc in B lymphomagenesis.
|
15743832 |
2005 |
Childhood Leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
TEL2 is expressed in the hematopoietic system, and its expression is up-regulated in bone marrow samples of some patients with leukemia, suggesting a role in oncogenesis.
|
16234363 |
2006 |
Childhood Leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
TEL2, an ETS factor expressed in human leukemia, regulates monocytic differentiation of U937 Cells and blocks the inhibitory effect of TEL1 on ras-induced cellular transformation.
|
15342392 |
2004 |
Nasopharyngeal carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
TEL2 expression was analyzed in three representative NPC cell lines expressing low levels of Snail (S26, 6-10B, HK1) and two cell lines expressing high levels of Snail (S18, 5-8F).
|
30253797 |
2018 |
Nasopharyngeal carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Collectively, we have provided the first evidence that TEL2 plays a key role in NPC metastasis by directly down-regulating SERPINE1, and that this novel axis of TEL2 / SERPINE1 may be valuable to develop new strategies for treating NPC patients with metastasis.
|
26335051 |
2015 |
Fanconi Anemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we show that FANCM and FAAP24 interact with the checkpoint protein HCLK2 independently of the FA core complex.
|
18995830 |
2008 |
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma.
|
23263282 |
2013 |
Myocardial Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Upregulating Tel2 expression increases mTOR-mediated cardiomyocyte survival and targeting Tel2 could be another therapeutic strategy against ischemic heart disease.
|
31323273 |
2019 |